Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

With the increase in large multimodal cohorts and high‐throughput technologies, the
potential for discovering novel biomarkers is no longer limited by data set size. Artificial …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

The gut microbiota (GM) and its metabolites affect the host nervous system and are involved
in the pathogeneses of various neurological diseases. However, the specific GM alterations …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by
cognitive decline, memory loss, and impaired daily functioning. The pathology of AD is …

Amyloid and tau biomarkers for Alzheimer's disease are widely recognized diagnostic tools
for the identification of Alzheimer's disease pathology antemortem and are recommended by …

In this review the applications of isotopically labeled compounds are discussed and put into
the context of their future impact in the life sciences. Especially discussing their use in the …

Increasing evidence shows that neuroinflammation is a possible modulator of tau spread
effects on cognitive impairment in Alzheimer's disease. In this context, plasma levels of the …

Purpose Amyloid positron emission tomography (PET) with [18F] florbetaben (FBB) is an
established tool for detecting Aβ deposition in the brain in vivo based on visual assessment …

Alzheimer's disease (AD) is a age-related neurodegenerative disease and is a major public
health concern both in Texas, US and Worldwide. This neurodegenerative disease is mainly …